Back

Estimate and prognosis of patients who are candidates for treatment with eicosapentaenoic acid after an acute coronary syndrome

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Lipids in heart disease Drug therapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Alberto Cordero

Hospital San Juan de Alicante, Alicante (Spain)

8 More presentations in this session

Presentation thumbnail
Is the obesity paradox leading to a less stringent secondary prevention strategy in post-acute coronary syndrome patients?
Mr M. Moreira (Penafiel, PT)
Abstract Slides Video
Presentation thumbnail
Outcomes of post-acute coronary syndrome patients enrolled in a phase 2 cardiac rehabilitation program
Mr M. Moreira (Penafiel, PT)
Abstract Slides Video
Presentation thumbnail
Temporal trends in lipid management among Korean patients following acute myocardial infarction from 2011 to 2020
Doctor S. Oh (Gwangju, KR)
Abstract Slides Video
Presentation thumbnail
Effect of triglycerides on cardiovascular risk in patients with a first vs. recurrent acute coronary syndrome
Doctor A. Cordero (Alicante, ES)
Abstract Slides Video
Presentation thumbnail
Statin use before acute coronary syndrome and coronary risk factors, clinical presentation, interventions, and outcomes: ACC-NCDR-CathPCI Registry in India
Professor R. Gupta (Jaipur, IN)
Abstract Slides Video

Access the full session

Session thumbnail
Lipids in heart disease

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Almost 1 in 2 patients with acute coronary syndrome are extremely high-risk and potential candidates for in-hospital triple lipid-lowering therapy: data from the CALLINICUS-Hellas Registry
thumbnail
Congress Presentation
Effect of triglycerides on cardiovascular risk in patients with a first vs. recurrent acute coronary syndrome
thumbnail
Congress Presentation
Clinical Case Introduction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources